FILANA THERAPEUTICS, INC.
Filana Therapeutics, Inc. (Nasdaq: FLNA) is a clinical-stage biotechnology company focused on developing transformative medicines for central nervous system disorders, particularly those associated with dysregulation or overexpression of filamin A protein. The company's lead therapeutic product candidate, simufilam,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What FILANA THERAPEUTICS, INC. does
In the company’s own words
Filana Therapeutics, Inc. (Nasdaq: FLNA) is a clinical-stage biotechnology company focused on developing transformative medicines for central nervous system disorders, particularly those associated with dysregulation or overexpression of filamin A protein. The company's lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment being studied for the treatment of tuberous sclerosis complex-related epilepsy and represents a potential first-in-class filamin A-modulating agent.
Simufilam was discovered and designed in-house and characterized through research collaborations conducted since approximately 2008. The drug works by modulating filamin A, a scaffolding protein in the brain that regulates neuronal cell development. Published research demonstrates that the combination of mTOR activation and filamin A overexpression causes cell overgrowth, abnormal connectivity, and brain malformations leading to seizures in TSC patients. While seizures have historically been treated with mTOR inhibitors, simufilam targets filamin A as a novel independent mechanism.
The company previously conducted an extensive clinical program evaluating simufilam for Alzheimer's disease, which was discontinued in early 2025 after two Phase 3 trials failed to meet efficacy endpoints. However, more than 2,000 patients were treated with simufilam during this program, with some receiving treatment for up to 24 months, establishing a favorable safety profile that remains relevant for TSC-related epilepsy development.
In February 2025, Filana entered into an exclusive worldwide license agreement with Yale University for intellectual property rights related to simufilam development and commercialization for TSC-related epilepsy and other potential indications. The company owns or controls a portfolio of issued patents and pending applications covering simufilam composition and methods of use across multiple jurisdictions, with U.S. patent protection extending through 2040.
Filana operates as a lean, narrowly focused organization outsourcing preclinical studies, clinical trials, and formulation development to third parties. The company manufactures simufilam through a supply agreement with Evonik Corporation, a leading contract development and manufacturing organization. Research and development expenses totaled $26.6 million in 2025. The company is classified as a smaller reporting company and emerging growth company.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1069530
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns FILANA THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · FILANA THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do FILANA THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of FILANA THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in FILANA THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”